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Introduction: Among the plethora of cells under investigation to restore a functional myocardium, mesenchymal
stromal cells (MSCs) have been granted considerable interest. However, whereas the beneficial effects of bone
marrow MSCs (BM-MSCs) in the context of the diseased heart are widely reported, data are still scarce on MSCs
from the umbilical cord matrix (UCM-MSCs). Herein we report on the effect of UCM-MSC transplantation to the
infarcted murine heart, seconded by the dissection of the molecular mechanisms at play.
Methods: Human umbilical cord tissue-derived MSCs (UCX®), obtained by using a proprietary technology
developed by ECBio, were delivered via intramyocardial injection to C57BL/6 females subjected to permanent
ligation of the left descending coronary artery. Moreover, medium produced by cultured UCX® preconditioned
under normoxia (CM) or hypoxia (CMH) was collected for subsequent in vitro assays.
Results: Evaluation of the effects upon intramyocardial transplantation shows that UCX® preserved cardiac function
and attenuated cardiac remodeling subsequent to myocardial infarction (MI). UCX® further led to increased
capillary density and decreased apoptosis in the injured tissue. In vitro, UCX®-conditioned medium displayed
(a) proangiogenic activity by promoting the formation of capillary-like structures by human umbilical vein
endothelial cells (HUVECs), and (b) antiapoptotic activity in HL-1 cardiomyocytes subjected to hypoxia. Moreover, in
adult murine cardiac Sca-1+ progenitor cells (CPCs), conditioned medium enhanced mitogenic activity while
activating a gene program characteristic of cardiomyogenic differentiation.
Conclusions: UCX® preserve cardiac function after intramyocardial transplantation in a MI murine model. The
cardioprotective effects of UCX® were attributed to paracrine mechanisms that appear to enhance angiogenesis,
limit the extent of the apoptosis, augment proliferation, and activate a pool of resident CPCs. Overall, these results
suggest that UCX® should be considered an alternative cell source when designing new therapeutic approaches to
treat MI.* Correspondence: perpetua@ineb.up.pt
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Cardiac diseases, in particular, ischemic heart disease,
represent a major cause of mortality and morbidity
worldwide, imposing a heavy economic burden on high-
and middle-income countries [1]. Myocardial infarction
(MI) is characterized by extensive cardiomyocyte death
and functional degradation of the cardiac tissue down-
stream from a coronary occlusion. After infarction, a
cascade of dramatic biochemical and morphologic
events, collectively designated cardiac remodeling, is ini-
tiated. These events culminate in the formation of a
nonfunctional scar in place of the damaged myocardium.
Currently, no therapeutic solutions are available for re-
placing the net loss of contractile tissue by new cardio-
myocytes. The only efficient long-term treatment is
heart transplant, which is impaired mainly by the short-
age of organ donors and the requirement for immuno-
suppression [2]. Consequently, cell therapies aimed at
directing heart’s response toward a more-efficient repair
and/or myocardial regeneration have received consider-
able attention in the last decade [3].
The potential for cardiac regeneration or, at the least,
for improving the myocardial repair process, is under
investigation for a plethora of different adult and
embryonic-derived cell populations [4]. Mesenchymal
stromal cells (MSCs) have taken special prominence be-
cause of their immunomodulatory role, which enables
major histocompatibility complex-mismatched allogen-
eic transplantation [5]. Although originally harvested
from the bone marrow [6,7], MSC-like cells have also
been identified in different tissues, and the most com-
mon sources are adipose tissue [8] and umbilical cord
tissue [9]. The use of allogeneic umbilical cord tissue,
namely umbilical cord matrix (Wharton's jelly), is advan-
tageous in comparison to any other source or because of
(a) the extraction process, i.e. absence of invasiveness
and higher efficiency, (b) higher MSCs cell yield [10],
and (c) the shorter MSCs doubling time, enabling a fas-
ter attainment of the abundant cell numbers required
for clinical use [11,12] while maintaining a safe profile.
Furthermore, we recently showed that UCX® were
more potent modulators of the immune system than
bone marrow-derived MSCs (BM-MSCs), being able to
repress T-cell activation and promote the expansion of
regulatory T cells more efficiently [13].
It has been extensively demonstrated that BM-MSCs
can be harnessed for cardiac repair [14-18], with clinical
trials showing promising results [19]. Several preclinical
studies have demonstrated the improvement of heart
function and the reduction of infarct size after MSCs
transplantation [20-25]. The cardioprotective mecha-
nisms exerted by MSCs appear to encompass (a) trans-
differentiation/fusion events [26-29], (b) attenuation of
cardiac remodeling [20,30-32], and (c) enhancement ofangiogenesis [25,33-35]. These appear to occur via cellu-
lar engraftment into the host myocardium [36] and/or
by a paracrine action (that is, favoring cardiac repair
by MSCs-secreted factors) [37]. MSCs are frequently
regarded as factories of cytokines and growth factors
[38,39] whose production is often increased under hyp-
oxic conditions [35]. The paracrine action of MSCs in
the context of MI has been demonstrated by the recap-
itulation of the cardioprotective effects attained by cell
transplantation through administration of the condi-
tioned medium produced in vitro by the same cells [40].
Although the beneficial effects of BM-MSCs in the
context of the diseased heart have been extensively re-
ported, data are still scarce on the effect of MSCs from
the umbilical cord tissue (UCM-MSC) [23,41-44]. Thus,
we set out to investigate the effect of transplantation of
a well-defined umbilical cord tissue-derived cellular
product (UCX®) on the heart of myocardial infarcted
mice, seconded by the dissection of the molecular mech-
anisms at play.
In this study, a specific population of human stem
cells derived from the umbilical cord tissue (Wharton’s
jelly), hereafter designated UCX®, was isolated, expanded,
and cryopreserved on the basis of proprietary technology
developed within our team [43]. We show that UCX® de-
livery into the myocardium of mice subjected to left
anterior descending (LAD) coronary artery ligation (a)
preserves heart function, (b) attenuates the cardiac re-
modeling process, (c) increases capillary density, and (d)
prevents apoptosis in the infarcted tissue. Moreover,
in vitro, we demonstrated that UCX® exerts a beneficial
effect on different cellular components of the myocar-
dium through paracrine mechanisms. Hence, UCX® pro-
tect cardiomyocytes from hypoxia-induced apoptosis,
enhance the formation of capillary-like structures by
endothelial cells, and trigger the differentiation of Sca-1+
adult cardiac progenitor cells (CPCs) [45].
Material and methods
Ethics and regulation
This study was approved by the Ethics Committee at the
Cascais Hospital Dr. José de Almeida, in the scope of a
research protocol between ECBio–Research & Develop-
ment in Biotechnology, S.A., and HPP Saúde–Parcerias
Cascais, S.A. In addition, all experimental research was
in compliance with the Helsinki Declaration. Umbilical
cord donations were obtained with written informed
consents, according to Directive 2004/23/EC, which sets
the standards of quality and safety for the donation, pro-
curement, testing, processing, preservation, storage, and
distribution of human tissues and cells [46]. All the
animal-testing procedures were subjected to approval by
the IBMC-INEB (Instituto de Biologia Molecular e Celu-
lar–Instituto de Engenharia Biomédica) Animal Ethics
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(permit 022793), and are in conformity with the Direct-
ive 2010/63/EU of the European Parliament [47]. Hu-
mane end points were followed in accordance to the
OECD Guidance Document on the Recognition, Assess-
ment, and Use of Clinical Signs as Humane End points for
Experimental Animals Used in Safety Evaluation [48].
UCX® isolation and ex vivo maintenance
Human UCX® were isolated according to [13] and pat-
ented proprietary technology [44] developed by ECBio.
In brief, fresh human umbilical cords were obtained
after term natural or C-section births, transported to the
laboratory facilities in a sterile container, and processed
within 48 hours. The procedure includes three recovery
phases to ensure a high cell yield and high isolation suc-
cess rates.
Isolated UCX® were cultured (up to P7) in Minimum Es-
sential Medium α (α-MEM; Gibco, Carlsbad, CA, USA),
1% P/S (100 U/ml Penicillin and 100 μg/ml Streptomycin,
Labclinics, Barcelona, Spain), buffered with 10 mM
HEPES (Gibco), hereafter designated Basal Medium (BM),
supplemented with 20% Fetal Bovine Serum (FBS; Lonza,
Basel, Switzerland), in a humidified incubator at 37°C and
5% CO2. Cells at confluence >90% were subcultured by
using Tryple Select (Gibco) as a detaching agent.
Myocardial infarction, UCX® delivery, and
echocardiography
Adult C57BL/6 mice (Charles River, Wilmington, MA,
USA) aged 8 to 12 weeks, were used for this study, inde-
pendent of gender. Myocardial infarction was experi-
mentally induced by LAD coronary artery ligation, as
previously described [49] with minor alterations. In brief,
mice were anesthetized by intraperitoneal injection (ip)
of medetomidine (1 mg/kg, Sededorm; ProdivetZN,
Lisboa, Portugal) and ketamine (75 mg/kg, Clorketam;
Vétoquinol, Lure, France), orally intubated, and mechanic-
ally ventilated by using a small-animal respirator (Minivent
845; Harvard Apparatus, Holliston, MA, USA). Animals
were kept on warming pads throughout the surgical
procedure and until full recovery. Under a stereomicro-
scope (Leica EZ4; Leica Microsystems, Wetzlar, Germany),
the heart was exposed (Ø 5 to 7 mm) via left thoracotomy
on the third intercostal space, and the pericardial sac was
gently disrupted. The first portion of the LAD coronary ar-
tery was visualized below the left atrium, as a pulsating
bright red vessel. A nonabsorbable 7.0 suture (Silkam; B.
Braun, Melsungen, Germany) was passed under the artery,
and the ligation was performed.
After LAD ligation, 2 × 105 UCX® in 0.5% Bovine
Serum Albumin (BSA; Merck, Whitehouse Station, NJ,
USA)/phosphate-buffered saline (PBS; Gibco) were de-
livered by four intramyocardial injections of 5 μl each,with a Hamilton syringe (Hamilton, Reno, NV, USA) at-
tached to a 30-gauge needle (n = 5). A group of control
animals (n = 10) were subjected to the same surgical pro-
cedure, although injected only with the vehicle (0.5%
BSA in PBS). The intercostal incision was closed by an
absorbable 6.0 suture (Safil; B. Braun), and surgical sta-
ples were used for skin closure. Anesthesia was reversed
by 5 mg/kg ip atipamezole (Revertor; Virbac, Carros,
France). Analgesia and fluid therapy were performed by
ip delivery of butorphanol (1 mg/kg; Butador; Richter
Pharma AG, Wels, Austria) and subcutaneous injection
of 5% glucose physiologic saline (B. Braun), respectively.
This procedure was repeated every 12 hours up to
72 hours after surgery or until full recovery.
Transthoracic echocardiography was performed at 7
and 14 days after LAD coronary artery ligation by using
a portable ultrasound apparatus (GE Vivid I; General
Electric, Fairfield, CT, USA) equipped with a 12-MHz
linear probe (GE 12 L-RS Linear Array Transducer;
General Electric). Animals were anesthetized (Clorke-
tam, 100 mg/kg) and placed on left lateral decubitus
position. Two-dimensional (2D) mode images of para-
sternal short-axis view were acquired to position the
Motion-mode (M-mode) cursor at the level of the papil-
lary muscles and perpendicularly to the interventricular
septum and left ventricle (LV) free-wall. To evaluate LV
structural changes, several parameters from M-mode
were measured (that is, the LV internal diameter at dia-
stole (LVIDd) and at systole (LVIDs). Left ventricular
ejection fraction (EF) and fraction shortening (FS) were
calculated as an index of systolic function: FS (%) =
((LVIDd - LVIDs)/LVIDd) × 100 and EF (%) = ((LVIDd3 –
LVIDs3)/LVIDd3) × 100. The same parameters were mea-
sured on control nonmanipulated (np) healthy animals
(n = 10).
Histologic procedures and immunohistochemistry
At 14 days after surgery, animals were deeply anesthe-
tized by ip injection of pentobarbital (Eutasil; CEVA,
Algés, Portugal, 70 mg/kg). After 4M potassium chlor-
ide (Sigma-Aldrich, St. Louis, MO, USA) injection,
diastole-arrested hearts were harvested, briefly washed
in PBS, and fixed in 10% formalin neutral buffer (Pro-
labo; VWR International, Radnor, PA, USA) up to
24 hours before paraffin embedding. Representative sam-
pling of the LV (approximately 12 sections, 3 μm) was
obtained by transverse sectioning from the apex to the
base of paraffin-embedded hearts with an interval of
300 μm between each section. Infarct-size assessment
was performed by staining paraffin sections with modi-
fied Masson trichrome staining (MT), according to the
Trichrome (Masson) Stain kit (Sigma-Aldrich), with
the following modifications: nuclei were prestained
with Celestine Blue solution after staining with Gill’s
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Bouin solution to promote uniform staining.
Immunostaining of heart sections were performed as
follows. After antigen recovery, sections were perme-
abilized with 0.2% Triton X-100 (Sigma-Aldrich) for 5 mi-
nutes and incubated 1 hour in 4% FBS/1% BSA in PBS for
blocking unspecific staining. For CD31 immunodetection,
sections were incubated with primary antibody (sc1506,
goat anti-mouse CD31; Santa Cruz Biotechnology, Dallas,
TX, USA), diluted 1:400 in the blocking solution, for
2 hours at room temperature (RT). Thereafter, sections
were incubated with the secondary antibody (A11057, 568
AlexaFluor donkey anti-goat IgG; Invitrogen) diluted
1:1,000 in blocking solution, for 1 hour at RT. Sections
were finally mounted by using Fluoroshield containing
DAPI (F6057; Sigma-Aldrich), for nuclei detection.
The extent of apoptosis in the cardiac tissue was
assessed by TUNEL assay (ApopTag Fluorescein In Situ
Apoptosis Detection Kit; Millipore, Billerica, MA, USA),
preceded by antigen recovery with Proteinase K (Sigma-
Aldrich; 20 μg/ml, for 15 minutes at 37°C). Images were
acquired with the inverted fluorescence microscope
Axiovert 200 Motorized and an AxioCam MRm camera
(Zeiss, Oberkochen, Germany). Quantification of apop-
totic and endothelial cells was performed by using
ImageJ 1.42 software (National Institutes of Health
(NIH), Bethesda, MD, USA).
Measurement of myocardial infarct size and
morphometric analysis
For infarct-size determination, the collagen deposition
highlighted (blue) in MT-stained sections was used to
define the LV scarred region. Images of histologic sec-
tions were captured with an Olympus SZX10 stereo-
microscope and Olympus DP21 camera (Shinjuku,
Tokyo, Japan). The percentage of the ischemic LV wall
was calculated by using the semiautomated software
MIQuant [50] by two different methods: the area meas-
urement [49] and the midline length measurement [51].
Morphometric analysis was performed by resorting to
Image J software (NIH). Wall thickness was calculated
as the average of the distance across the wall of five
equidistant points of the ischemic wall. Lumen-area per-
centage was calculated by the ratio between the lumen
delimited by the endocardium and the total LV area.
Conditioned medium collection and processing
UCX® was seeded in BM supplemented with 5% FBS and
grown until 90% confluence. After washing cells with
PBS, BM (without serum) was added, and 24 hours
preconditioning under normoxia (37°C, 5% CO2) or
hypoxia (37°C, 5% CO2, 1% O2) was performed.
Thereafter, BM was replaced and conditioned for
48 hours at 37°C and 5% CO2, after which it wascollected, centrifuged at 300 g for 10 minutes to remove
cell debris, filtered (0.22-μm pore size, Millipore), and
concentrated in 5-kDa cut-off spin concentrators (Agi-
lent Technologies, Santa Clara, CA, USA). Conditioned
medium produced by UCX® subjected to normoxia
(CMN) or hypoxia (CMH) was frozen at −80°C for fur-
ther use.
Apoptosis assay
The cardiomyocytic cell line HL-1 was maintained in
Claycomb supplemented medium (SAFC Biosciences,
Lenexa, KS, USA), according to authors instructions (please
refer to [52] for details). HL-1 cells were seeded (50,000
cells/cm2) on Ø 5-mm coverslips (Thermo Scientific, Wal-
tham, MA, USA) overnight. Immediately before subjecting
HL-1 to hypoxia (1% O2), medium was changed to Clay-
comb basal medium supplemented with either (a) α-MEM
basal medium (BM); (b) concentrated CMN, (c) concen-
trated CMH (ninefold dilution), or (d) BM+ 10% FBS. After
48 hours of hypoxia (n = 3), HL-1 cells were fixed in 1%
paraformaldehyde (PFA; Sigma-Aldrich) in PBS (15 mi-
nutes, RT), and the percentage of apoptotic cells was deter-
mined by using the ApopTag kit (Millipore) followed by
image acquisition by the inverted fluorescence microscope
Axiovert 200 (Zeiss).
Vasculogenesis assay
The vasculogenesis assay was performed as described in
[53], by using the thick gel method of preparation. In
brief, Matrigel growth factor reduced (BD Biosciences,
San Jose, CA, USA) was thawed overnight and poured
carefully into eight-well chamber slide LabTeks (Nalgene
Nunc, Thermo Scientific; 105 μl/well), followed by incu-
bation at 37°C for 45 minutes to allow jellification. After-
wards, human umbilical vein endothelial cells (HUVECs;
Science Cell 8000; Corte Del Cero, Carlsbad, CA, USA)
up to P10 were cultured (45,000/cm2) on top of Matrigel
in Endothelial Basal Medium-2 (EBM-2; Lonza) + 1%
P/S supplemented (1:9 dilution) with (a) α- MEM basal
medium (BM), conditioned medium produced by UCX®
subjected to (b) normoxia (CMN) or (c) hypoxia (CMH)
preconditioning. After incubation at 37°C and 5% CO2
for 3.5 hours, cells were washed in PBS and stained with
Calcein AM (C1430; Invitrogen) Images were acquired
by using the inverted fluorescence microscope Axiovert
200 (Zeiss). Tube formation, number of branching
points, and tube length and thickness were manually
measured by using ImageJ1.42 (NIH), analyzing approxi-
mately 25 fields per replicate (n = 3).
Isolation and culture of adult murine heart Sca-1+ cardiac
progenitor cells (CPCs)
Sca-1+ CPCs were extracted and selected by immuno-
magnetic cell sorting (MACS; Miltenyi Biotec, Bergisch
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C57BL/6 mice were harvested, dissociated by using the
GentleMACS Dissociator (Miltenyi Biotec), and digested
with 600 U/ml Collagenase II (4176; Worthington,
Lakewood, NJ, USA) and 60 U/ml DNAseI (A3778;
Applichem Lifesciences, Gatersleben, Germany) for 30
minutes at 37°C with agitation (100 rpm). Immunomag-
netic cell sorting was performed by incubating the
single-cell suspension with Sca-1-FITC antibody (MACS;
Miltenyi Biotec) followed by anti-FITC Microbeads
(MACS; Miltenyi Biotec). Sca-1+ CPCs were maintained
in α-MEM basal medium (BM) supplemented with 10%
FBS. Cells were split at 90% confluence and used until
passage 3.
Sca-1+ CPCs metabolic activity, proliferation assessment,
and quantitative real-time PCR (qRT-PCR)
Sca-1+ CPCs were trypsinized and seeded in four different
media: (a) α-MEM basal medium (BM); (b) basal medium
supplemented with 10% FBS (BM+ FBS); (c) CMN; or (d)
CMH. After 72 hours of culture, media were replaced by
10% resazurin (R7017; Sigma-Aldrich) in BM and incu-
bated for 3 hours, after which absorbance at 590 nm was
measured. Metabolic activity values are expressed relative
to BM treatment for each initial cell-plating density.
Proliferation was assessed by Ki67 immunostaining in
CPCs fixed in 4% PFA and permeabilized with 0.2%
Triton-X for 2 minutes. After blocking with 4% FBS/1%
BSA in PBS for 1 hour, cells were incubated with anti-Ki67
primary antibody (1:200, ab15580; Abcam, Cambridge,
England) overnight at 4°C and subsequently with the sec-
ondary antibody Alexa Fluor 568 donkey anti-rabbit (1:300,
A-10042; Invitrogen), for 2 hours at RT. Images were ac-
quired by the inverted fluorescence microscope Axiovert
200 (Zeiss), and percentage of Ki67+ cells was manually de-
termined by counting approximately five fields with 30 to
50 cells per field, per replicate and medium condition.
For qRT-PCR, RNA was extracted by using RNAeasy
extraction kit (Qiagen, Hilden, Germany) and reverse
transcribed by using PrimeScriptRT reagent kit (RR037A;
Takara, Tokyo, Japan). PCR was performed by using the
iQSYBR Green SuperMIX (BioRad, Hercules, CA, USA)
and according to the iQ5 Real-Time PCR Detection Sys-
tem (BioRad). Primer sequences and temperature cycles
will be available on request. mRNA expression was de-
fined as primer efficiency to the power of the difference in
threshold cycle values between the gene of reference
(GADPH) and the gene of interest. Values were expressed
relative to those derived from CPCs cultured in standard
conditions (BM + 10% FBS).
Data and statistical analysis
Values presented in text and figures are as mean ± stand-
ard error of the mean of at least three independentexperiments. Statistical analysis was performed by using
Graph Pad Prism (v5, La Jolla, CA, USA) software, eval-
uated by unpaired one-way ANOVA test by using
Newman-Keuls post hoc test for correction of multiple
comparisons, and differences were considered significant
when *P < 0.05, **P < 0.01, or ***P < 0.0001.
Results
Intramyocardial transplantation of UCX® preserves cardiac
performance and attenuates adverse LV remodeling
2 weeks after MI
UCX® were isolated by using a proprietary method
(PCT/IB2008/054067) that yields a well-defined number
of cells by using a precise proportion between tissue-
digestion enzyme activity units, tissue mass, digestion solu-
tion volume, and void volume. These cells displayed plastic
adherence, fibroblast-like morphology, and an antigenic
profile typical of mesenchymal stromal cells [13] (see
Additional file 1: Figure S1), as defined by the International
Society for Cellular Therapy [54].
To evaluate the therapeutic potential of the UCX® in
an MI setting, cells were delivered via intramyocardial
injection to mice subjected to permanent ligation of the
LAD coronary artery. Infarcted animals that received
only the vehicle were used as control. Transthoracic
echocardiography performed at 1 and 2 weeks after MI
revealed consistent LV-chamber dilation and impaired
LV function in all MI groups (Figure 1A through D). Al-
though no beneficial effect of UCX® delivery could be
recognized at 1 week after MI, a tendency to decreased
EF and FS in transplanted hearts was evident (Figure 1C,
D). Conversely, at 2 weeks after MI, a significantly re-
duced diastolic LV-chamber dilation could be verified in
cell-transplanted mice when compared with the vehicle
control group (Figure 1A, B). Moreover, although not
reaching statistical significance, EF and FS had inverted
the tendency observed at 1 week and were augmented
in the cell-transplanted group when compared with
vehicle-injected hearts (Figure 1C, D). Overall, UCX®
transplanted hearts preserved systolic function 2 weeks
after surgery, contrarily to the progressive loss of cardiac
function observed in the vehicle group.
Widespread cell death and degradation of the cardiac
extracellular matrix in the ischemic myocardium culmi-
nates in a substantial thinning of the LV wall, LV chamber
dilation, and formation of a collagenous-rich nonfunc-
tional scar; alterations that are commonly designated as
cardiac remodeling. Stereoscopic view of representative
cross-sections of infarcted hearts harvested at 2 weeks
after surgery showed that LV free-wall thinning and LV
chamber dilation occurred in both experimental groups
(Figure 1E). Morphometric analysis of the LV cross-
sections revealed that UCX® transplanted hearts exhibited
a less-pronounced decrease (by 41.1% ± 13.8%) in
Figure 1 Intramyocardial delivery of UCX® preserved cardiac function and attenuated cardiac remodeling after MI. (A, B) Transthoracic
echocardiography, at 2 weeks after transplantation, demonstrated a significant reduction in diastolic LVID and a more subtle reduction in systolic LVID in
the UCX® transplanted group (n= 5) when compared with vehicle-injected animals (n= 10). (C, D) EF and FS of UCX®-transplanted hearts was preserved
from 1 to 2 weeks after injury, contrarily to the progressive decrease of the systolic function observed in the vehicle-injected group. (E) Masson Trichrome
stain on histologic sections representative of the LV highlight the collagen deposition (blue) on the infarcted region. Thinning of the LV wall and LV
dilatation was observed in the UCX® (n= 5), as well as in the vehicle (n= 10) experimental groups. (F) MI size was quantified by two different methods:
the area measurement and the midline length measurement, and no significant differences were identified between groups. When compared with the
vehicle control group the UCX®-transplanted group showed a smaller reduction of the LV wall thickness (G) and a less-pronounced LV dilation
(H), indicative of UCX®-mediated tapering of cardiac remodeling after MI. LVIDd, left ventricular internal diameter at diastole; LVIDs, left ventricular internal
diameter at systole; EF, ejection fraction; FS, fractional shortening; n (nonmanipulated) = 10. *P< 0.05; scale bar = 2 mm.
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control group. Moreover, the UCX®-injected group dis-
played a 40.8% ± 7.2% reduction in the endocardial diam-
eter, relative to the vehicle-control (Figure 1H), similar to
what was observed in the echocardiographic assessment
of the LVIDd (Figure 1A). These data suggest an UCX®-
mediated cardiac protective effect through attenuation of
the infarct expansion and LV remodeling after MI.
Despite these evidences, no differences in infarct size
(calculated on the basis of collagen deposition) were ob-
served between vehicle and UCX® transplanted MI ani-
mals (Figure 1F).
UCX® cells stimulate angiogenesis and prevent apoptosis
in the infarcted myocardium
To evaluate whether the cardiac improvement observed
after MI could be in part a result of improved neovascu-
larization, CD31-expressing cells (CD31+) were immu-
nolabeled and counted in the infarcted and peri-infarcted
regions of all experimental groups. Quantification of
CD31+ cells demonstrated a clear increase in the number
of endothelial cells of the microvasculature on UCX®-
transplanted hearts (Figure 2B) over the vehicle group
(Figure 2A). This increase was more pronounced in the
myocardium adjacent to the ligation region (32.9% ± 7.8%)Figure 2 Transplantation of UCX® into MI hearts increased capillary den
injected (n = 6, A and D) and UCX®-transplanted hearts (n = 5, B and E) staine
green). (C) CD31-expressing cells were more abundant within the infarcted LV
control group. (F) UCX®-transplanted hearts showed fewer apoptotic cells in t
an anti-apoptotic protective effect by the UCX®. Green filter in A and B denotthan in the apex region (25.3% ± 11.8%) of the LV
(Figure 2C).
Moreover, the anti-apoptotic potential of UCX® was
evaluated on the infarcted and peri-infarcted regions
(Figure 2D and E). The number of apoptotic cells in the
apex of UCX®-transplanted hearts was reduced by 39.0%
± 8.7% when compared with the same region of vehicle-
injected hearts (Figure 2F).
Although a beneficial effect of UCX® in cardiac repair
following MI could be established, it remained to be eluci-
dated whether functional and histologic improvement was
a direct result of UCX® engraftment in the injured hearts.
To assess this, paraffin-embedded heart tissue sections
were stained with a monoclonal antibody directed against
the nuclei of human cells. Nuclear-specific staining could
not be found (see Additional file 1: Figure S2), indicating
that UCX® did not engraft the murine heart in this experi-
mental setting. Human muscle tissue subjected to similar
processing was used as positive control.
UCX® enhances cellular vasculogenesis in vitro via a
paracrine mechanism
Given that UCX® did not engraft murine hearts, we postu-
lated that the observed cardioprotective effects could have
been exerted primarily through paracrine mechanisms.sity and decreased apoptosis. Representative images of vehicle–
d for CD31 (A and B, red) and for cellular apoptosis (D and E, bright
wall of UCX®-transplanted hearts when compared with the vehicle
he apical region when compared with vehicle-injected hearts, suggesting
es tissue autofluorescence. *P < 0.05; scale bars = 100 μm.
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to either normoxia (CMN) or hypoxia (CMH) precondi-
tioning was collected for further investigation. Because
UCX® enhanced the number of cells expressing the proto-
typical endothelial marker CD31 in MI-hearts in vivo, we
addressed whether the UCX®-conditioned media were able
to enhance the formation of capillary-like structures by
endothelial cells (HUVECs) in vitro, by using a classic vas-
culogenesis assay (Matrigel). In comparison with HUVECs
seeded in endothelial basal medium (EBM-2) supple-
mented with BM (Figure 3A), cells cultured in CMN
(Figure 3B) or CMH-supplemented media (Figure 3C)
showed an increased number of capillary-like structures
(by 42.7% ± 5.6% in CMN and 53.1% ± 4.7% in CMH,
Figure 3D), as well as branching points (by 35.8% ± 5.6%
in CMN and 47.4% ± 4.3% in CMH, Figure 3E). TheFigure 3 Paracrine effect of UCX® in in vitro vasculogenesis by HUVEC
supplemented with BM (A), CMN (B) or CMH (C) for 3,5 hours. Cells seeded
(D, by 42.7% ± 5.6% in CMN and 53.1% ± 4.7% in CMH) and branching poin
pro-angiogenic effect. The tubes formed in CMN- or CMH-supplemented m
CMH) and thicker (G, by 81.4% ± 6.8% in CMN and 94.8% ± 8.8% in CMH), i
observed in vivo vasculogenic effect. ***P < 0.0001.caliber of the tubes formed was also affected, as HUVECs
cultured in CMN- or CMH-supplemented EBM-2 displayed
lengthier (by 35.8% ± 3.2% in CMN and 55.5% ± 3.7% in
CMH, Figure 3F) and thicker (by 81.4% ± 6.8% in CMN and
94.8% ± 8.8% in CMH, Figure 3G) capillary-like structures,
when compared with BM-supplemented medium. These re-
sults strongly support that UCX® favors angiogenic pro-
cesses by a paracrine mechanism, thus corroborating the
aforementioned in vivo observations (Figure 2A through C).
UCX® display a paracrine protective effect against the
apoptotic damage of HL-1 cardiomyocytes in vitro
The UCX®-mediated apoptotic protective effect detected
in transplanted MI hearts (Figure 2D through F) led us
to investigate whether UCX®-conditioned medium reca-
pitulated such effects in vitro.s. Matrigel assay was performed by seeding HUVECs in EBM-2
in UCX®-conditioned media formed more capillary-like structures
ts (E, by 35.8% ± 5.6% in CMN and 47.4% ± 4.3% in CMH), suggesting a
edia were longer (F, by 35.8% ± 3.2% in CMN and 55.5% ± 3.7% in
n comparison to those formed in BM, further corroborating the
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http://stemcellres.com/content/5/1/5For this purpose, the HL-1 cell line, a gold-standard
system for investigating cardiomyocytes in vitro, was
used. These cells are able to maintain a differentiated
cardiac phenotype while beating in culture.
HL-1 cells subjected to hypoxic conditions for 48 hours
increased the apoptotic rate by approximately 2.4-fold in
serum-supplemented medium and to 3.6-fold in serum-
free medium (Figure 4A through C). UCX®-CMN and
CMH significantly halved the number of TUNEL-positive
cells when compared with BM (Figure 4D through F). No
significant differences were found in the protection against
the hypoxia-induced HL-1 apoptotic damaged between
CMN and CMH.
UCX®-derived conditioned media stimulate resident
CPCs proliferation and activate a cardiomyogenic
gene-expression program
Whereas the reportedly low proliferation of mature cardio-
myocytes [55] makes it an unlikely event to be accom-
plished in the time frame of our experimental in vivo
setting, a stimulation and/or activation of the myocardium
undifferentiated cells cannot be disregarded. Therefore, to
further dissect the mechanisms involved in UCX®-mediated
beneficial effects in MI, we addressed whether resident
CPCs could be responsive to UCX® conditioning. Sca-1+Figure 4 Paracrine effect of UCX® in hypoxia-induced apoptosis of HL
protect HL-1 cardiomyocytes from apoptosis (induced by hypoxia during 4
(F) The percentage of apoptotic cells increases when cells are subjected
and serum-free BM medium (47.73% ± 2.02%). Importantly, when media
of apoptotic cells is significantly decreased (CMN – 24.77% ± 1.70%; CMHCPCs were maintained in either BM, BM-supplemented
with FBS, UCX®-CMN, and UCX®-CMH for 72 hours. Al-
though the treatment with both UCX®-conditioned media
favored CPCs metabolic activity (Figure 5A) relative to
basal culture medium, a differential effect was observed be-
tween CMN and CMH concerning CPCs proliferation and
commitment. Hence, although both CMN and CMH en-
hanced the proliferation of Sca-1+ CPCs, this effect was
more pronounced in response to CMN (Figure 5B). More-
over, higher expression levels of early (Gata4, Nkx2.5) and
late (α heavy chain subunit of cardiac myosin, Myh6) car-
diac markers revealed that the UCX®-CMH triggers Sca-1+
CPCs cardiomyogenic commitment, when compared with
the other experimental groups (Figure 5C through G).
CMN also induced the expression by CPCs of Gata-4 and
Myh6, however, not attaining the levels observed with
CMH. Importantly, the results displayed in Figure 5 were
verified for three independent experiments (each per-
formed in duplicate) with different batches of conditioned
media as well as different preparations of primary cells.
Discussion
Previous studies have demonstrated that BM-MSCs trans-
plantation has the potential to improve cardiac function
and LV remodeling after infarction [56-60]. However, in-1 cardiomyocytes. (A through E) UCX®-derived CMN or CMH
8 hours), as shown by the detection of apoptotic cells by TUNEL assay.
to hypoxia for 48 hours, both in serum-containing (31.93% ± 1.59%)
are supplemented with UCX® conditioned media, the percentage
– 23.67% ± 1.95%). ***P < 0.0001, n = 4.
Figure 5 Paracrine effect of UCX® on CPCs proliferation and cardiac commitment. Treatment of Sca-1+ CPCs with UCX®-derived conditioned
media for 72 hours results in enhanced metabolic activity (A) and cellular proliferation (B), when compared with the treatment with basal
medium (n = 4; *P < 0.05; **P < 0.01; ***P < 0.0001). (C through E) Treatment with UCX®-derived CMH and, to a lesser extent, CMN triggers CPCs
cardiac commitment, as shown by higher expression of early (Gata4, Nkx2.5) and late (Myh6) cardiac-affiliated markers in comparison with
basal-medium treated CPCs (n = 3; values were normalized to those of standard culture conditions: BM + 10% FBS, represented by the dotted lines
in each graph. *P < 0.05; **P < 0.01, either between groups indicated in brackets, or between BM + 10% FBS and the group represented by the
asterisk placed above its corresponding column).
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http://stemcellres.com/content/5/1/5clinical terms, the use of BM-MSCs presents some severe
limitations: (a) the procurement process requires an inva-
sive surgical procedure, (b) the BM-MSCs frequency in
the native tissue is very low (1:10,000 total cells in bone
marrow), resulting in heterogeneous BM-MSCs prepara-
tions that are difficult to replicate; (c) the efficiency of
BM-MSCs isolation is also highly dependent on the pa-
tient’s clinical history and on the adopted isolation
process, and finally, (d) BM-MSCs isolation, in a clinical
setting, involves complex logistics and specialized clinicians,which very seldom occur concomitant with common
hospital environments [12,61]. In the present work, MSCs
isolated from the umbilical cord Wharton’s jelly using
technology developed by us, and designated UCX®, come
forth as an allogeneic, off-the-shelf cell-product that can
be further regarded as the active substance for advanced
therapeutic options towards restoration of the injured
myocardium. In this MI murine model, UCX® transplant-
ation preserves cardiac function after MI through para-
crine mechanism(s) that involve the attenuation of the LV
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http://stemcellres.com/content/5/1/5remodeling process and anti-apoptotic as well as pro-
angiogenic effects. Potential mechanisms involved in the
UCX®-mediated cardiac protection were further dissected
in vitro by the use of UCX® conditioned media. UCX®
paracrine effects involve the (a) protection of cardiomyo-
cytes from hypoxia-induced apoptosis, (b) increase in
forma-tion of capillary-like structures by endothelial cells,
and (c) promotion of resident Sca-1+ CPCs proliferation
and cardiac commitment.
Although a clear definition of the mechanisms in-
volved in the use of MSCs as therapeutic agents for MI
is not available at this point, a panoply of MSCs-
mediated beneficial effects on cardiac function have been
reported (apoptosis, scar formation, and angiogenesis)
by using different cell sources (for example, bone mar-
row, adipose tissue) and animal models (for example,
rat, pig). In this work, we showed that UCX® transplant-
ation precludes a worsened prognosis of MI over time,
contributing to the preservation of cardiac function
(% EF and % FS). Moreover, histologic beneficial out-
comes were shown on UCX® transplantation, such as
an increase in LV wall thickness and lower LV dilation,
as reported by others [21,24,25]. Likewise, our data cor-
roborates that a benefic effect of MSCs occurs through
the enhancement of angiogenesis [33] and inhibition of
apoptosis [62].
Furthermore, a novel aspect in this work is the indica-
tion of alternative mechanisms that could account for
the cardioprotective activity of UCX® (that is, identifica-
tion of a potential to activate the cardiac commitment/
differentiation and/or augment the frequency of undif-
ferentiated Sca-1+ CPCs). In this regard, hypoxia precon-
ditioning of UCX® may play an important role in the
determination of cell-fate choice and thereby the func-
tion of CPCs. Although both UCX®-conditioned media
preparations enhanced CPCs metabolic activity, distinct
actions were also evident. Thus, CMN displayed higher
mitogenic activity, whereas CMH had a more pro-
nounced effect in the activation of Sca-1+ CPCs cardiac
commitment, as shown by the higher levels of Nkx2.5,
Gata4. and Myh6 expression observed in this condition.
To the best of our knowledge, this is the first report on
the paracrine effects of MSCs in the pool of adult resi-
dent undifferentiated cells. Moreover, BM-MSCs have
already been shown to affect the differentiation of pro-
genitors isolated from the neonatal heart [63]. Hence, it
will be of importance to establish whether the MSCs-
mediated effects on CPCs observed in vitro correlate
with the benefits shown after MSCs transplantation in
the onset of MI.
Our study expands the knowledge on the yet-unexplored
potential of MSCs derived from umbilical cord tissue to
repair the injured heart. Although much work has focused
on the properties of MSCs of several distinct sources, onlyone other study has addressed the umbilical cord tissue-
derived cells [23]. The latter reports on transplantation of
MSCs in a rabbit MI model as leading to a modest func-
tional recovery of the LV in chronic conditions (30 days
after MI), but not in the acute phase (5 days after MI). The
cardioprotective effect was attributed to moderate engraft-
ment of the xenotransplanted cells, which expressed imma-
ture cardiac markers, despite not being able to differentiate
fully into functional cardiomyocytes.
Thus, while corroborating such data, we report on the
benefits of UCM-MSCs transplantation in cardiac function
after MI in a murine model, and provide additional mech-
anistic insight into the cardioprotective effects observed.
The UCX® were not found to engraft the murine heart
in our setting. Nonetheless, despite the high immuno-
logic barrier to xenotransplantation, adding to the hos-
tile inflammatory milieu triggered by MI, and the low
dose of administered cells (that is, 2 × 105 cells/heart),
the UCX® exerted a beneficial effect in murine infarcted
hearts. Although not addressed in the current study, the
UCX® likely interfered with the initial events of acute in-
flammation characteristic of MI, therefore attenuating
LV-remodeling processes, while also favoring angiogenic
and cardioprotective effects.
Due the well-acknowledged immunomodulatory na-
ture of MSCs, and in particular, that of the MSCs iso-
lated from the umbilical cord tissue [13], persistence of
cells in a human allogeneic transplantation may be con-
ceivably higher, thereby enhancing the cardioprotective
effects mediated by the paracrine action herein de-
scribed. This must be considered when designing new
cell therapies (that is, cells could be either transplanted
to assure prolonged release of factors [64], or alterna-
tively, could be used for producing factors for subse-
quent administration to the patient.
Administration of UCX®-conditioned medium into the
MI border zone may clarify whether paracrine factors solely
are responsible for the effects after UCX®-transplantation.
Noteworthy, conditioning by the host tissue of the
UCX® after transplantation should not be neglected, as
it may lead to the production of paracrine factors that
are unlikely replicated by the infusion of conditioned
media derived from in vitro cultured cells. Future work
will be conducted to elucidate this particular aspect.
Aiming at a clear indication of which factors could
account for the UCX® mediated beneficial effects, the
gene-expression pattern of UCX® was assessed with Affi-
metrix gene array [GEO:GSE51869] by using cells derived
from three different umbilical cords (see Additional file 1:
Figure S3). When comparing the expression of those
genes with that of positive (CD105, CD73, CD90, and
CD44) and negative (CD14, CD19, CD34, CD45, CD31,
and HLA-DR) markers of UCX®, it is concluded that
the expression of angiogenesis-associated transcripts
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TGF-β, and PDGF-AB) is high. Therefore, several factors
are most likely contributing for the cardioprotective ef-
fects observed in vivo and in vitro. More-directed work is
already under way specifically to identify the role of each
of the candidates. Nevertheless, the specific function of
these factors in cardiomyocytes protection, vasculogenesis,
and CPC induction must be further investigated for clarifi-
cation of each of these three mechanisms separately.
Yet another approach to enhance cellular paracrine
action is to engineer cells to promote their cardioprotec-
tive activity. This has been clearly demonstrated in the
work by Mangi and colleagues [65]. By genetically engin-
eering rat BM-MSCs to overexpress the prosurvival
Akt-1 gene, a dramatic contribution for the restoration
of cardiac function (evaluated ex vivo), and prevention
of adverse tissue remodeling, was obtained by intramyo-
cardial transplantation after MI.
Noteworthy, the method of UCX® extraction and sub-
sequent processing has been recently adapted to ad-
vanced therapy medicinal product (ATMP) standards, as
defined by the guideline on the minimum-quality data
for certification of ATMP (EMA/CAT/486831/2008/corr,
2010). Given that our effects UCX® exert in the context
of MI, a future clinical usage of this off-the-shelf cellular
product can be envisaged.Conclusions
Human mesenchymal stromal cells derived from the
umbilical cord matrix (UCX®) preserve cardiac function
and attenuate adverse tissue remodeling after intramyo-
cardial transplantation in a murine MI model. The cardi-
oprotective effect of UCX® is exerted through paracrine
mechanism(s) that appear to (a) enhance angiogenesis,
(b) limit the extent of the apoptosis in the heart, and
(c) to increase proliferation and activate the cardiomyo-
genic gene-expression program in a pool of myocardial
resident cardiac progenitor cells.Additional file
Additional file 1: The supplementary material includes three
additional Figures (Figure S1, Figure S2, and Figure S3) with additional
results. The file also includes the respective legend captions and methods.
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